Replimune surges day after FDA Commissioner Makary resigns
Source: SeekingAlpha
2026-05-13 13:07:30 ET
More on Replimune Group
- Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1
- Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives
- Replimune: Multiple Shots On Goal But A High Risk Binary Approaches
- FDA head Makary defends drug application rejections amid criticism
- RFK Jr. says no hand in rejecting Replimune’s lead asset
Read the full article on Seeking Alpha
For further details see:
Replimune surges day after FDA Commissioner Makary resigns
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
28.78% G/L:
$5.19 Last:
9,599,164 Volume:
$3.99 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
